Namasthe

Find the healthcare and drug approval news of India, China, Japan, Australia and other Asian countries

Biogen Announces Approval of Leqembi for Alzheimer’s Disease in Hong Kong | iPharmaCenter

Biogen and Eisai have announced that the Department of Health in Hong Kong has approved Leqembi (lecanemab) for the treatment of...

Brazil and Thailand Introduce New Single-Dose Malaria Cure to Combat Plasmodium vivax | iPharmaCenter

Brazil and Thailand have become the first malaria-endemic nations to launch tafenoquine, a new single-dose medication aimed at preventing...

AstraZeneca Granted CDSCO Authorization for Andexanet Alfa: Antidote for Severe Bleeding Tied to FXa Inhibitors AstraZeneca announced...

South Korea Healthcare News - MoHW aims to support supply of essential medicines | iPharmaCenter

The Ministry of Health and Welfare (Minister: Cho Gyu-hong) has announced that starting from December 1, measures such as an increase in...

COVID-19 India Updates | Covaxin approved for children | Vaccines for teenagers

India started vaccination of adolescents; Bharat Biotech says Covaxin demonstrated robust efficacy and safety in people of age 2-18 years...

China released the 2022 NDRL list, Chinese pharma benefited from the list

China has released the 2021 Drug catalog, which included 2,860 drugs, out of which 1,486 drugs are Western drugs. Reuters reported a...

WHO granted EUL to Covaxin; acclaims easy storage requirement

WHO has announced that it has granted emergency use listing for Covaxin developed by Bharat Biotech. This adds another vaccine to the...

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Novartis entered a strategic collaboration with BeiGene to license tislelizumab; to market in major markets outside China, including...

Bayer submitted vericiguat for market authorization in China

Bayer has announced that it has submitted an application requesting the approval of vericiguat in China for the treatment of chronic...

Bayer’s Xofigo received approval for prostate cancer in China

Bayer has announced that the Chinese National Medical Products Administration (NMPA) approved Xofigo (radium-223 dichloride) for treating...

Merck’s Keytruda received one more indication and dosage form approval in Japan

Merck has announced that it has received the approval of its anti-PD-1 therapy, Keytruda (pembrolizumab) for radically unresectable,...

AZ received one more approval in Japan, received approval of Imfinzi for SCLC

The Japanese Ministry of Health, Labor, and Welfare approved AstraZeneca’s Imfinzi (durvalumab) for treating patients with...

JAPAN HEALTHCARE SYSTEM

INTRODUCTION Japan has a population of 126 million, nearly twice the size of the UK population. Japan is the third-largest economy. The...

China’s National Medicinal Products Administration approved Gilead’s Truvada

Gilead has announced that China’s National Medicinal Products Administration has approved Truvada (emtricitabine 200mg/tenofovir...

Eisai's Dayvigo was approved in Japan and Hong Kong for insomnia

Approval of Dayvigo in Japan On July 6th, 2020, Eisai announced that it had launched Dayvigo (lemborexant) in Japan for insomnia. The...

Merck’s Keytruda approved in China for esophageal squamous cell carcinoma

Merck has announced that it has received approval from the Chinese National Medical Products Administration (NMPA) in China for Keytruda...

GSK and Clover Biopharmaceuticals begins COVID-19 vaccine Phase 1 clinical trial

GSK has announced that Clover Biopharmaceuticals initiated the Phase 1 trial of COVID-19 vaccine SCB-2019. The vaccine was given in...

May witnessed the approval of Pfizer’s Talzenna, Nyprax’s Tukysa, Drug Houses’ Ajovy in Singapore

In Singapore, the Health Sciences Authority has approved three new products in May. Ajovy approved for migraine in adults Tuksya approved...

Gilead announced the positive Phase 3 trial of remdesivir in COVID-19 patients

Gilead has announced top-line Phase 3 trial results of remdesivir in patients with COVID-19. The drug is indicated in moderate COVID-19...